Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: A meta-analysis

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4401-4409

  Ping, Wei ^a   Sun, Wei ^a   Zu, Yukun ^a   Chen, Wenshu ^a   Fu, Xiangning ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Esophageal squamous cell carcinoma; Hypoxia inducible factor 1 ; Meta analysis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHINESE BIOMEDICAL LITERATURE DATABASE; CLINICAL FEATURE; COCHRANE LIBRARY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EMBASE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EVALUATION STUDY; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR INVASION; WEB OF SCIENCE; ESOPHAGUS TUMOR; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PUBLISHING; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROGNOSIS; PUBLICATION BIAS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902971465     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1579-0     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99:860-8. (Pubitemid 34575705)
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50. (Pubitemid 46655601)
4. Tanaka T, Ishiguro H, Kuwabara Y, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res. 2010;29:83.
5. Takatori H, Natsugoe S, Okumura H, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008;34:397-402. (Pubitemid 351381291)
6. Sasaki K, Natsugoe S, Ishigami S, et al. Significance of twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2009;28:158.
7. Okamoto H, Fujishima F, Nakamura Y, et al. Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol. 2013;11:51.
8. Matsuyama T, Nakanishi K, Hayashi T, et al. Expression of hypoxia-inducible factor-1(alpha) in esophageal squamous cell carcinoma. Cancer Sci. 2005;96:176-82. (Pubitemid 40575919)
9. Kimura S, Kitadai Y, Tanaka S, et al. Expression of hypoxia-inducible factor (HIF)-1(alpha) is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004;40:1904-12. (Pubitemid 39036767)
10. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47. (Pubitemid 37328806)
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-32. (Pubitemid 37328811)
12. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493-7. (Pubitemid 34462724)
13. Oh SY, Kwon HC, Kim SH, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer. 2008;8:123.
14. Dai CX, Gao Q, Qiu SJ, et al. Hypoxia-inducible factor-1alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer. 2009;9:418.
15. Hung JJ, Yang MH, Hsu HS, et al. Prognostic significance of hypoxia-inducible factor-1alpha, Twist1 and snail expression in resectable non-small cell lung cancer. Thorax. 2009;64:1082-9.
16. Zhang H, Duan X, Duan Z, et al. Expression of HIF-1α and its prognostic significance in esophageal squamous cell carcinoma. Chin Cancer Res Prev Treat. 2006;33:602-4.
17. Tzao C, Lee SC, Tung HJ, et al. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers. 2008;25:141-8.
18. Ogane N, Yasuda M, Shimizu M, et al. Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol. 2010;14:23-9.
19. Fan XL, Liu WQ, Mao Y, et al. Association of HIF-1(alpha) and Tiam1 expression with tumor invasion, lymph node metastasis, and prognosis in patients with esophageal carcinoma. World Chin J Digestol. 2012;20:590-5.
20. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor-1(alpha) (HIF-1(alpha)) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89:1042-7. (Pubitemid 37239209)
21. Katsuta M, Miyashita M, Makino H, et al. Correlation of hypoxia inducible factor-1α with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol. 2005;78:123-30. (Pubitemid 40248793)
22. Chen Y, Lu Y, Lu C, et al. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1(alpha) expression. Pathol Oncol Res. 2009;15:487-93.
23. Munipalle PC, Viswanath YKS, Davis PA, et al. Prognostic value of hypoxia inducible factor-1(alpha) in esophageal squamous cell carcinoma. Dis Esophagus. 2011;24:177-81.
24. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110:838-44. (Pubitemid 38758509)
25. Wu XA, Sun Y, Fan QX, et al. Relationship between the expression of hypoxia-inducible factor 1(alpha) and chemotherapy response in esophageal squamous cell carcinoma. Natl Med J China. 2007;87:1783-5. (Pubitemid 47527553)
26. Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000
27. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
28. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Stat Med. 1998;17:2815-34. (Pubitemid 28562978)
29. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ: Br Med J. 2003;327:557.
30. DerSimonian R, Laird N.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
32. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62:97-128.
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
34. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. (Pubitemid 27387172)
35. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90:4304-8. (Pubitemid 23134215)
36. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 2007;12:853-9. (Pubitemid 47554628)
37. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71. (Pubitemid 15107153)
38. Xu XL, Ling ZQ, Chen W, et al. The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: a meta-analysis. Cancer Biomark. 2013;13:105-13.
39. Li L, Zhao J, Wu Z, et al. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther. 2009;30:589-96.
40. Sun G, Hu W, Lu Y, et al. A meta-analysis of HIF-1alpha and esophageal squamous cell carcinoma (ESCC) risk. Pathol Oncol Res. 2013;19:685-93.
41. Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48:2787-92. (Pubitemid 38989137)
42. Ren W, Mi D, Yang K, et al. The expression of hypoxia-inducible factor-1alpha and its clinical significance in lung cancer: a systematic review and meta-analysis. Swiss Med Wkly. 2013;143:w13855.
43. Zheng SS, Chen XH, Yin X, et al. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e65753.
44. Zhang ZG, Zhang QN, Wang XH, et al. Hypoxia-inducible factor 1 Alpha (HIF-1alpha) as a prognostic indicator in patients with gastric tumors: a meta-analysis. Asian Pac J Cancer Prev. 2013;14:4195-8.
45. Welsh SJ, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003;2:235-43.
46. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3:363-75. (Pubitemid 38340305)
47. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946-56. (Pubitemid 38868141)
48. Lee K, Qian DZ, Rey S, et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A. 2009;106:2353-8.
49. Wong CC, Gilkes DM, Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011;108:16369-74.
50. Wong CC, Zhang H, Gilkes DM, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl). 2012;90:803-15.
51. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-5.
52. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A. 1996;93:1988-92. (Pubitemid 26079868)
53. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656-60.
54. Egger M, Zellweger-Zahner T, Schneider M, et al. Language bias in randomised controlled trials published in English and German. Lancet. 1997;350:326-9. (Pubitemid 27351115)